OBJECTIVE: Pharmacologic agents designed to promote mucociliary clearance (MCC) in chronic rhinosinusitis (CRS) represent a novel therapeutic strategy. The objectives of the present study were to investigate whether the natural bioflavonoid hesperidin 1) increases transepithelial chloride (Cl(-)) secretion in vitro and in vivo, 2) enhances ciliary beat frequency (CBF), and 3) exerts its mechanistic effects through cAMP/PKA-dependent pathways. STUDY DESIGN: In vitro and in vivo study. SETTING: Laboratory. SUBJECTS AND METHODS: Transepithelial Cl(-) transport (Ussing chamber) and CBF were investigated in primary murine nasal septal (MNSE) and human sinonasal epithelial (HSNE) cultures. In vivo activity was measured using the murine nasal potential difference (NPD) assay, cystic fibrosis transmembrane conductance regulator (CFTR) R-domain phosphorylation, and cAMP levels were investigated to rule out a cAMP/PKA-dependent mechanism of activation. RESULTS: Hesperidin significantly increased CFTR-mediated Cl(-) transport (change in short-circuit current, DeltaI(SC)) in both MNSE (13.51 +/- 0.77 vs 4.4 +/- 0.66 [control]; P < 0.05) and HSNE (12.28 +/- 1.08 vs 0.69 +/- 0.32 [control]; P < 0.05). Cl(-) transport across in vivo murine nasal epithelium was also significantly enhanced with hesperidin (-2.3 +/- 1.0 vs -0.8 +/- 0.8 mV [control], P < 0.05). There was no increase in cellular cAMP or phosphorylation of the CFTR R-domain. Hesperidin significantly increased CBF (ratio of pretreatment to post-treatment) with both basal (1.31 +/- 0.07 vs 0.93 +/- 0.06 [control]; P < 0.05), apical (1.72 +/- 0.09 vs 1.40 +/- 0.07 [control]; P < 0.05), and basal + apical delivery (2.26 +/- 0.18 vs 1.60 +/- 0.21, respectively; P < 0.05). CONCLUSION: Our in vitro and in vivo investigations provide strong support for future testing of this robust Cl(-) secretagogue and CBF activator in human clinical trials for CRS. Copyright 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
OBJECTIVE: Pharmacologic agents designed to promote mucociliary clearance (MCC) in chronic rhinosinusitis (CRS) represent a novel therapeutic strategy. The objectives of the present study were to investigate whether the natural bioflavonoidhesperidin 1) increases transepithelial chloride (Cl(-)) secretion in vitro and in vivo, 2) enhances ciliary beat frequency (CBF), and 3) exerts its mechanistic effects through cAMP/PKA-dependent pathways. STUDY DESIGN: In vitro and in vivo study. SETTING: Laboratory. SUBJECTS AND METHODS: Transepithelial Cl(-) transport (Ussing chamber) and CBF were investigated in primary murine nasal septal (MNSE) and human sinonasal epithelial (HSNE) cultures. In vivo activity was measured using the murine nasal potential difference (NPD) assay, cystic fibrosis transmembrane conductance regulator (CFTR) R-domain phosphorylation, and cAMP levels were investigated to rule out a cAMP/PKA-dependent mechanism of activation. RESULTS:Hesperidin significantly increased CFTR-mediated Cl(-) transport (change in short-circuit current, DeltaI(SC)) in both MNSE (13.51 +/- 0.77 vs 4.4 +/- 0.66 [control]; P < 0.05) and HSNE (12.28 +/- 1.08 vs 0.69 +/- 0.32 [control]; P < 0.05). Cl(-) transport across in vivo murine nasal epithelium was also significantly enhanced with hesperidin (-2.3 +/- 1.0 vs -0.8 +/- 0.8 mV [control], P < 0.05). There was no increase in cellular cAMP or phosphorylation of the CFTR R-domain. Hesperidin significantly increased CBF (ratio of pretreatment to post-treatment) with both basal (1.31 +/- 0.07 vs 0.93 +/- 0.06 [control]; P < 0.05), apical (1.72 +/- 0.09 vs 1.40 +/- 0.07 [control]; P < 0.05), and basal + apical delivery (2.26 +/- 0.18 vs 1.60 +/- 0.21, respectively; P < 0.05). CONCLUSION: Our in vitro and in vivo investigations provide strong support for future testing of this robust Cl(-) secretagogue and CBF activator in human clinical trials for CRS. Copyright 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
Authors: Zsuzsa Bebok; James F Collawn; John Wakefield; William Parker; Yao Li; Karoly Varga; Eric J Sorscher; J P Clancy Journal: J Physiol Date: 2005-10-06 Impact factor: 5.182
Authors: Marcelo B Antunes; Bradford A Woodworth; Geeta Bhargave; Guoxiang Xiong; Jorge L Aguilar; Adam J Ratner; James L Kreindler; Ronald C Rubenstein; Noam A Cohen Journal: Biotechniques Date: 2007-08 Impact factor: 1.993
Authors: Shaoyan Zhang; James A Fortenberry; Noam A Cohen; Eric J Sorscher; Bradford A Woodworth Journal: Am J Rhinol Allergy Date: 2009 Mar-Apr Impact factor: 2.467
Authors: Nathan S Alexander; Neal Hatch; Shaoyan Zhang; Daniel Skinner; James Fortenberry; Eric J Sorscher; Bradford A Woodworth Journal: Laryngoscope Date: 2011-04-07 Impact factor: 3.325
Authors: Shaoyan Zhang; Nicholas Smith; Daniel Schuster; Christopher Azbell; Eric J Sorscher; Steven M Rowe; Bradford A Woodworth Journal: Am J Rhinol Allergy Date: 2011 Sep-Oct Impact factor: 2.467
Authors: Annette Ehrhardt; W Joon Chung; Louise C Pyle; Wei Wang; Krzysztof Nowotarski; Cory M Mulvihill; Mohabir Ramjeesingh; Jeong Hong; Sadanandan E Velu; Hal A Lewis; Shane Atwell; Steve Aller; Christine E Bear; Gergely L Lukacs; Kevin L Kirk; Eric J Sorscher Journal: J Biol Chem Date: 2015-12-01 Impact factor: 5.157
Authors: Do-Yeon Cho; Daniel Skinner; Shaoyan Zhang; James Fortenberry; Eric J Sorscher; Nichole R Dean; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2015-12-03 Impact factor: 3.858
Authors: Nathan S Alexander; Angela Blount; Shaoyan Zhang; Daniel Skinner; Stephen B Hicks; Michael Chestnut; Frederick A Kebbel; Eric J Sorscher; Bradford A Woodworth Journal: Laryngoscope Date: 2012-04-20 Impact factor: 3.325
Authors: Nichole Dean; Neel K Ranganath; Brandon Jones; Shaoyan Zhang; Daniel Skinner; Steven M Rowe; Eric J Sorscher; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2014-04-14 Impact factor: 3.858